期刊文献+

终末期肾病患者骨折影响因素的Meta分析

Risk factors for fracture in patients with end-stage renal disease:a Meta-analysis
下载PDF
导出
摘要 目的系统分析终末期肾病患者发生骨折的相关因素。方法计算机检索中国知网、维普、万方、中国生物医学数据库、PubMed以及EMBASE中自建库以来公开发表的相关文献。由2名研究员独立筛选文献、提取资料、纳入文献质量评价,采用Review Manager 5.3软件进行统计分析。结果共纳入19篇文献,合并结果提取8个相关影响因素,其中6个危险因素:年龄(OR=1.28,95%CI:1.20~1.37,P<0.01)、女性(OR=1.93,95%CI:1.51~2.46,P<0.01)、碱性磷酸酶(OR=1.03,95%CI:1.01~1.05,P=0.008)、甲状旁腺激素(OR=1.07,95%CI:1.04~1.10,P<0.01)、糖尿病(OR=1.70,95%CI:1.44~2.02,P<0.01)、透析年限(OR=1.83,95%CI:1.20~2.80,P=0.005);2个保护因素:血清白蛋白(OR=0.81,95%CI:0.69~0.96,P=0.02)和活性维生素D3(OR=0.33,95%CI:0.16~0.67,P=0.002)。结论年龄≥65岁、女性患者、碱性磷酸酶升高、甲状旁腺激素过高或过低、透析年限>6年以及合并糖尿病是终末期肾病患者骨折的危险因素,正常的血清白蛋白和活性维生素D3是降低骨折发生的保护因素。 Objective To systematically explore the factors related to fractures in patients with end-stage renal disease(ESRD).Methods The authors conducted a computerized search of CNKI,VIP,Wanfang,China Biomedical Database,PubMed and Embase for the relevant literature published since their inceptions.Two researchers independently selected and evaluated the quality of the studies,extracted data and utilized Review Manager 5.3 software for statistical analysis.Results A total of 19 articles were retrieved.Among 8 related factors,6 of them were risk factors as follows:age(OR=1.28,95%CI:1.20-1.37,P<0.01),female(OR=1.93,95%CI:1.51-2.46,P<0.01),alkaline phosphatase(OR=1.03,95%CI:1.01-1.05,P=0.008),parathyroid hormone(OR=1.07,95%CI:1.04-1.10,P<0.01),diabetes mellitus(OR=1.70,95%CI:1.44-2.02,P<0.01),duration of dialysis(OR=1.83,95%CI:1.20-2.80,P=0.005)and two protective factors of serum albumin(OR=0.81,95%CI:0.69-0.96,P=0.02)and activated vitamin D3(OR=0.33,95%CI:0.16-0.67,P=0.002).Conclusion Risk factors for fracture in ESRD patients include age≥65 years,female,elevated alkaline phosphatase,abnormal level of parathyroid hormone,dialysis duration>6 years and concurrent diabetes mellitus.Normal levels of serum albumin and activated vitamin D3 are protective factors for fracture.
作者 黄健芳 石钰 彭红梅 黄霞 Huang Jian-fang;Shi Yu;Peng Hong-mei;Huang Xia(Department of Nephrology,Xinqiao Hospital,Army Medical University,Chongqing 400037,China)
出处 《临床肾脏病杂志》 2023年第6期480-486,共7页 Journal Of Clinical Nephrology
基金 重庆市科卫联合医学科研项目(2021MSXM313)。
关键词 终末期肾病 骨折 碱性磷酸酶 End-stage renal disease Fracture Alkaline phosphatase
  • 相关文献

参考文献5

二级参考文献47

  • 1王汉民,于艳.肾性骨病药物治疗进展[J].世界临床药物,2006,27(2):86-89. 被引量:6
  • 2顾波,路建饶.尿毒症中高磷和心血管钙化研究新进展[J].国际泌尿系统杂志,2006,26(4):566-568. 被引量:5
  • 3宦红娣,张景红.甲状旁腺激素的功能及其在肾性骨病发病中的作用[J].中国中西医结合肾病杂志,2007,8(3):182-184. 被引量:12
  • 4Mathew S, Lund R J, Strebeck F. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soe Nephrol, 2007,18( 1 ) :122 - 130.
  • 5Jamal SA, Hodsman AB. Reducing the risk of re - fracture in the dialysis population : is it time to consider therapy with PTH analogues ? Semin Dial, 2011,24 ( 1 ) : 12 - 15.
  • 6Ochiai M, Nakashima A, Takasugi N, et al. Vitamin K2 alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract, 2011, 117(1) :15 -19.
  • 7Gal -Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to para- thyroid hormone levels. Clin Nephro1,2005,65 (4) :284 -289.
  • 8Iwasaki Y, Yamato H, Nil - Kono T, et al. Insufficiency of PTH action on bone in uremia. Kidney Int suppl,2006, (102) :S34 - S36.
  • 9Frazao JM, Martins P. Adynamic bone disease : clinical and ther- apeutic implications. Curr Opin Nephrol Hypertens, 2009, 18 (4) :303 -307.
  • 10Kansal S, Fried L. Bone disease in elderly individuals with CKD. Adv Chronic Kidney Dis ,2010,17 (4) :41 - 51.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部